Korro Bio (KRRO) Company Value to Net Income

Corporate emblem and logo of Korro Bio (KRRO)

The current Korro Bio, Inc. (KRRO) share price chart on GURU.Markets with the -1.90 indicator highlights the startup's risks: a lack of profitability and massive development costs amid potential legal disputes. Meanwhile, the market already prices in R&D expenses, anticipating the imminent launch of human trials. Visionary management aims to correct genetic defects via RNA, attracting top industry experts.

KRRO korrobio.com: Price to Earnings Ratio in the range 02/21/2024 - 11/12/2026

Comprehensive metric breakdowns and analytics for Korro Bio Inc. (KRRO)

- share price and expert price forecast:
Price Performance Chart Korro Bio, Inc|KRRO - Price Target Chart
- market capitalization details:
Market Value Korro Bio, Inc.|KRRO - Total Company Value
- balance sheet net asset value indicators:
Net Asset Value per Share Korro Bio|KRRO - Company Net Assets|Market Value to Book Value korrobio.com|KRRO - Company Total Assets
- company liabilities and liquidity data:
Debt to Equity Korro Bio, Inc.|KRRO - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Korro Bio, Inc|KRRO - Company Debts|Debts to Book Value Korro Bio, Inc.|KRRO - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Korro Bio|Interim Coverage Ratio korrobio.com
- business earnings and investment ratios data:
KRRO - Company Net Income|Net Profit Forecast Korro Bio, Inc.|KRRO - P/E Multiple|Projected Price to Earnings Korro Bio, Inc|KRRO - Price/Earnings to Growth Multiple|Total Company Value to Operating Income Before Depreciation Ratio Korro Bio, Inc.|KRRO - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Korro Bio|KRRO - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months korrobio.com|KRRO - Earnings per share growth in current year|Expected earnings per share trend next year Korro Bio, Inc.
Comprehensive company analysis:KRRO (korrobio.com)
Brand item of korrobio.com

Korro Bio, Inc. (KRRO) utilizes a flexible outsourcing model that minimizes capital expenditures, which directly impacts the price-to-earnings ratio dynamics. This multiple compares market capitalization to net income, measuring investors' willingness to pay a premium for future growth. Analysis of the curve allows for an assessment of the Fed's interest rates on the company's asset values. The indicator's final vector determines the balance between inflationary risks and the business's real value.

Competing companies

TEM: Company Value to Net Income|Price to Earnings Ratio Qiagen (QGEN)|IONS (Ionis Pharmaceuticals, Inc.) - Company Value to Net Income|Price to Earnings Ratio Repligen Corp. RGEN|Avidity Corp (RNA) - Market Cap to Earnings|CRSP: Price to Earnings Ratio|Company Value to Net Income WGS (genedx.com)|RARE: P/E Multiple|BEAM (Beam Therapeutics Inc) - Price to Earnings Ratio|SRPT (Sarepta Therapeutics Inc) - P/E Multiple|Twist Bioscience Corp (TWST) - Business Payback Period|Price to Earnings Ratio 10x Genomics, Inc. (TXG)|NTLA - Market Cap to Earnings|Stoke Therapeutics, Inc. - Price to Earnings Ratio|Company Value to Net Income BLFS|Wave Life Sciences Corp - P/E Multiple|Business Payback Period Maze Therapeutics Corp MAZE|Sionna Therapeutics Inc (SION) - Price to Earnings Ratio|Price to Earnings Multiple PRME|TSHA (Taysha Gene Therapies, Inc.) - P/E Multiple|Price to Earnings Ratio uniQure NV (QURE)|Price to Earnings Ratio MGTX (MeiraGTx PLC)|Business Payback Period REGENXBIO Corp|Price to Earnings Ratio Solid Biosciences Inc. SLDB|P/E Multiple ocugen.com OCGN|PACB - Price to Earnings Ratio|Company Value to Net Income BNTC (Benitec Biopharma Inc)|Design Pharma (DSGN) - Price to Earnings Ratio|Rocket Corp - Company Value to Net Income|Price to Earnings Ratio 4D Molecular Therapeutics|Market Cap to Earnings Lexeo LXEO|P/E Multiple EDIT|Silence Therapeutics PLC - Price to Earnings Multiple|Price to Earnings Ratio ProQR Therapeutics PRQR|CDXS: Price to Earnings Multiple|Sangamo Therapeutics - P/E Multiple|NAUT - P/E Multiple|Metagenomi (MGX) - Price to Earnings Ratio|precisionbiosciences.com (DTIL) - P/E Multiple|Price to Earnings Ratio Generation Bio Co|Market Cap to Earnings Boundless Bio Inc BOLD|Price to Earnings Ratio Exicure, Inc. (XCUR)|IMNN (imunon.com) - Company Value to Net Income|Price to Earnings Ratio Phio Pharmaceuticals Corp. PHIO|Company Value to Net Income MBIO|RNAZ - Price to Earnings Ratio|Market Cap to Earnings Bionano Genomics, Inc.|APDN (Applied DNA Sciences) - Price to Earnings Ratio|bluebirdbio.com - Company Value to Net Income|IPA (ImmunoPrecise Antibodies Ltd) - P/E Multiple|Price to Earnings Ratio OMGA|P/E Multiple OMIC|Business Payback Period Regulus|Price to Earnings Ratio Syros Pharmaceuticals SYRS|telesisbio.com (TBIO) - Market Cap to Earnings|TCON: Price to Earnings Ratio|Company Value to Net Income UBX (Unity Biotechnology Inc.)